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These two groups of investigators identified simultaneously the
same disease, named SeSame and EAST syndrome, respec-
tively, acronyms based on the clinical abnormalities found in
this disease (seizures or epilepsy, sensorineural deafness,
ataxia, mental retardation and tubulopathy). This new autoso-
mal recessive disorder was described from the study of six
kindreds. In four of them, parental consanguinity was docu-
mented.
All affected patients initially presented with generalized sei-
zures in infancy. Later, they developed speech and motor delay
and marked ataxia. Brain magnetic resonance imaging did not
show significant lesions, except volume loss of cerebellum in
rare patients. Sensorineural hearing loss was noted from the
ages of 1 to 18 yr.
All affected patients had hypokalemic metabolic alkalosis,
hypomagnesemia, and hypocalciuria. Renin-angiotensin-aldo-
sterone system was stimulated. BP was normal. By ultrasonog-
raphy, kidneys were normal. Electrolyte imbalance mimics
Gitelman syndrome; however, neurologic involvement makes
the difference.
Genome-wide linkage analysis was performed on four infor-
mative families and identified a single significant locus on
chromosome 1q23.2 with a logarithm of odds score of 3.00 and
4.98, respectively. The linked interval contains 70 well-defined
and at least six hypothetical genes. Attention was focused on
KCNJ10, which encodes the inwardly rectifying K channel
Kir4.1, which consists of two transmembrane segments and one
pore. KCNJ10 had been shown to be expressed in the central
nervous system, cochlea, and distal nephron. A mouse knock-
out has a neurologic phenotype similar to that seen in the
patients.
Various homozygous or compound heterozygous mutations
were identified in KCNJ10 in affected patients. Heterologous
expression of wild-type KCJN10 in Xenopus oocytes resulted in
robust currents. In contrast, currents from KCNJ10 mutants
were reduced in the study by Bockenhauer et al.
In normal mice, the presence of Kcnj10 was demonstrated on
the basolateral membrane of the distal convoluted tubule, the
connecting tubule, and the early cortical collecting duct. No
signal was detected in Kcnj10 knockout mice. These mice die
very early as a consequence of central nervous system symp-
toms. They also had diminished growth, renal salt wasting, and
decreased calcium urinary excretion. Conditional knockout in
glial cells resulted in death later in life, suggesting that renal
salt loss is an aggravating factor in the mice with complete
knockout.
Kir4.1/5.1 heteromultimers are located in the basolateral
membrane of the distal nephron (more specific, in the distal
convoluted tubule, the only tubular site at which inhibition of
NaCl reabsorption produces hypomagnesemia and reduced
calcium excretion). These multimers recycle potassium that
enters the cell via the Na-K-ATPase back into the interstitial
space and contribute to the negative membrane potential that
promotes basolateral Cl exit. Loss of Kir4.1 activity inhibits the
function of Na-K-ATPase via loss of K recycling, reduces
basolateral Cl reabsorption by rendering the membrane poten-
tial less negative, and thereby inhibits both apical sodium and
Cl reabsorption by NCCT and Mg2 reabsorption by TRPM6
because of a less negative membrane potential. The resulting
renal salt loss activates the renin-angiotensin-aldosterone sys-
tem.
In the brain, KCNJ10 seems to be primarily expressed in glial
cells. Some Mendelian seizure disorders have already been
described, involving K or Na channels.
Kir4.1 is expressed in intermediate cells of the stria vascu-
laris, where it is believed to contribute to the generation of
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the endocochlear potential. As emphasized by Claude Amiel
several decades ago, there are many analogies between co-
chlear and renal physiology and pathology. Single-gene mu-
tations may produce effects on both systems. For example,
loss-of-function mutations in ATP6B1, which encodes a sub-
unit of the H-ATPase, result in distal tubular acidosis and
sensorineural hearing loss. Similarly, mutations in Barttin,
which encodes a subunit of some Cl channels, result in both
Bartter syndrome and deafness. Not surprising, inherited
channel or transporter disorders bridge the gap between
medical disciplines and open new avenues for further re-
search (1).
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Occurrence of hypomagnesemia (serum Mg2 levels 0.7
mmol/L) in the general population has been estimated to be
approximately 2%. The kidney is central for the maintenance
of the Mg balance. A large body of knowledge has been
generated from the study of inherited defects of renal Mg2
handling. The majority of filtered Mg is reabsorbed along
the proximal tubule and thick ascending limb of Henle’s loop
via a passive paracellular pathway. Claudin 16, formerly
paracellin 1, and claudin 19 are renal tight junction proteins
that are important for paracellular reabsorption of calcium
and magnesium in thick ascending limb. Mutations of the
corresponding genes, CLDN 16 and 19, result in a rare au-
tosomal recessive tubular disorder that is characterized by
familial hypomagnesemia, hypercalciuria, and nephrocalci-
nosis (FHHNC). This disease is frequently associated with
progressive renal failure as a result of both intrarenal cal-
cium deposition and additional roles of claudins in the main-
tenance of tight junction integrity. Children with a complete
loss of function of CLDN16 have a more rapid progression of
renal failure than those with residual function (1).
The thiazide-sensitive sodium chloride co-transporter in the
distal convoluted tubule (DCT) is mutated in Gitelman syn-
drome. Hypokalemic metabolic alkalosis and hypocalciuria are
associated with hypomagnesemia. At the apical membrane of
DCT cells is also present the Mg2-permeable transient recep-
tor potential cation channel, subfamily M (TRPM6). Mg2 up-
take from the tubular fluid via TRPM6 is primarily driven by
the negative potential across the luminal membrane. Hypo-
magnesemia with secondary hypocalcemia is caused by muta-
tions in TRPM6.
Mutations in FXYD2, encoding the -subunit of the basolat-
eral Na-K-ATPase, is responsible for dominant isolated renal
Mg2 wasting, as a result of misrouting of this subunit. This
defect has been described so far in a single family (but read this
summary to the end). Finally, the recently discovered magne-
siotropic hormone EGF causes isolated recessive renal hypo-
magnesemia (see references in Glaudemans et al.).
Glaudemans et al. identified a new mechanism for autosomal
dominant hypomagnesemia. A large Brazilian family was stud-
ied. Twenty-one affected members had serumMg2 levels0.4
mmol/L, which was responsible for muscle symptoms and
tetany from infancy.
The locus was identified on chromosome 12. The mutation
was found in KCNA1, a gene encoding the voltage-gated K
channel, Kv1.1. This channel co-localized with TRPM6 along
the luminal membrane of DCT. Upon overexpression in a hu-
man kidney cell line, patch-clamp analysis revealed that the
mutation resulted in a nonfunctional channel, with a dominant
negative effect on wild-type Kv1.1 channel function. The neg-
ative potential across the apical membrane is normally main-
tained by an apical K efflux via Kv1.1 energized by the action
of Na-K-ATPase. When Kv1.1 function is lost, Mg2 reab-
sorption in DCT is impaired.
Recently, an unexpected mechanism of renal magnesium
wasting and hypomagnesemia was discovered by Adalat et
al. (2). They first identified a teenager who had hepatocyte
nuclear factor 1B (HNF 1B) mutation and presented with
tetany and hypomagnesemia (0.620 mmol/L). Then they ret-
rospectively reviewed 91 pediatric cases of renal malforma-
tion screened for HNF 1B mutation. Twenty-one had het-
erozygous mutations. Eight (44%) of 18 mutation carriers
had hypomagnesemia (0.65 mmol/L) compared with one
(2%) of 48 of those without mutations. HNF 1B is a transcrip-
tion factor that is expressed in developing kidneys, whereas,
postnatally, proximal and distal tubules express the gene.
Hnf 1b in mouse upregulates transcription of various genes
whose human homologues are involved in inherited cystic
kidney diseases. Adalat et al. (2) detected a highly conserved
HNF 1B recognition site in FXYD2. They demonstrated HNF
1B–mediated transactivation of FXYD2. Thus, HNF 1B regu-
lates transcription of FXYD2, which participates in the tubu-
lar handling of Mg2. These results extend the phenotype of
HNF 1B mutations to include hypomagnesemia. Serum
Mg2 levels should be measured in patients with HNF 1B
mutations (2).
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Two regular articles and one commentary are devoted to idio-
pathic retroperitoneal fibrosis (RPF) in the July issue ofMedicine
(1). This is a good opportunity to brush up our knowledge (and
ignorance) on this rare disease. Unfortunately, these two arti-
cles discuss only marginally the therapeutic problems raised by
this disease.
The prospective study by van Bommel et al., based on 53
cases collected in 10 yr, shows that the annual incidence of 1.3
cases per 100 000 inhabitants in the Netherlands is higher than
that previously assumed. Mean age at diagnosis (64 yr; range 34
to 82 yr) was higher than in previous studies and in that by
Scheel and Feeley (54.25 yr; range 23 to 74 yr). This is explained
by the different inclusion criteria in the two studies (see later).
The clinical presentation of RPF has been known for decades
and is confirmed by the findings of the two recent series. Pain
(lower back, abdomen, or flank) is the most common symptom,
often more severe at night, radiating to the groin or to hip.
Weight loss was found in 40% of the patients studied by van
Bommel et al. In men, testicular pain with or without scrotal
swelling is frequent. High erythrocyte sedimentation rate and
other markers of inflammation are more pronounced in women
than in men. Sixty-six percent of the patients presented with
impaired renal function as a result of unilateral or bilateral
hydroureteronephrosis.
The diagnosis of idiopathic RPF was based on contrast-en-
hanced computed tomography (CT) in the study by van Bom-
mel et al. and/or magnetic resonance imaging in that by Scheel
and Feeley, showing a well-defined soft-tissue density envel-
oping but not displacing the lower aorta with caudal extension
following the bifurcation of the iliac vessels. Malignancy was
ruled out on the basis of clinical and radiologic investigations;
however, van Bommel et al. underlined that localized lymph-
adenopathies, usually with diameter 1 cm, adjacent to RPF
mass were frequently noted. Scheel and Feeley stated that RPF
is a form of periarteritis and that all patients who did not meet
the aforementioned requirements should undergo biopsy (nine
of 53 patients in the series by van Bommel et al.).
The main difference between the studies rests on the limits of
idiopathic RPF regarding changes of the abdominal aorta:
Scheel and Feeley excluded patients with aneurysmal dilation,
whereas, in the study by van Bommel et al., 23% of the patients
(versus 4.6% in a similarly aged healthy population) had aortic
aneurysms. This explains why patients of the latter series were
older and why men predominate: 41 of 53 were men versus 26
of 48 in the former series. This accounts for the striking differ-
ences in hypertension and cardiovascular diseases (40% of the
patients studied by van Bommel et al.) between the studies. This
also raises the question of the definition of “idiopathic” RPF:
Should patients with increased aortic diameter (60% in the
Dutch study) or with atherosclerotic changes be excluded or
not from this entity? It is usually considered that RPF is sec-
ondary to advanced aortic wall atherosclerosis, possibly
through an autoallergic reaction to components of the athero-
sclerotic plaque. The concept of idiopathic RPF’s being a sys-
temic autoimmune disorder has been diversely appreciated
and is not supported by the results of van Bommel et al. (1).
Four additional morphologic findings emerged from these
two recent studies. First, RPF mass can extend up to or above
the level of the renal vessels (in three patients, 6% in the Dutch
series). Two patients in the series of Scheel and Feeley had
significant renal artery stenosis that required endovascular
stenting. Iliac artery stenosis or pelvic vein compression or
thrombosis may occur in some patients. Five patients (9% in the
Dutch study) presented with a bulky mass extending into the
pelvis. These atypical forms should be known; biopsy is indi-
cated for these localized tumors. Second, Scheel and Feeley
proposed a classification system based on imaging: Class I, RPF
surrounding only infrarenal aorta; class II, fibrosis embedding
inferior vena cava; class III, lateral extension with compression
of one or two ureters; and class IV, extension to the renal hilum.
Third, pathologic 68Ga or 18FDG uptake at the level of the RPF
plaque was found by van Bommel et al. in 70% of the cases.
This demonstrates that the RPF mass is metabolically active and
vascularized. Extra-abdominal uptake was noted in 11% of the
patients. It would be of interest to know whether the response
to steroid therapy correlated with the intensity of the uptake.
Fourth, chest CT scanning is valuable in patients with RPF.
Uibu et al. (2) found that asbestosis was a risk factor for RPF
(odds ratio 8.8 for 10 fiber-years). This is confirmed in the
prospective study by van Bommel et al. Chest CT scans showed
unilateral or bilateral pleural plaques or thickening in seven
men (17% of the 41 male patients). Six of these seven patients
were occupationally exposed to asbestos. No evidence of me-
sothelioma was found in these patients. Should these cases be
considered “idiopathic” RPF? Regarding differential diagnosis,
Scheel and Feeley excluded nine patients who did not meet the
criteria for diagnosis. Two had aneurysmal dilation of the aorta,
one had postsurgical scarring, three had a malignant disease
including one lymphoma, and three had Erdheim-Chester dis-
ease. This rare non–Langerhans cell histocytosis or juvenile
xanthogranulomas may encompass retroperitoneal involve-
ment, in association with bone pain and osteosclerosis, fever,
exophthalmos, central diabetes insipidus, and other systemic
symptoms (3). Retroperitoneal involvement clearly differs from
idiopathic RPF. Atypical soft tissue infiltrates the retroperito-
neal space, is less dense than idiopathic RPF, and surrounds the
kidneys.
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The spectrum of predisposing factors to atypical hemolytic
uremic syndrome (aHUS) is widening. This syndrome includes
cases of HUS that are not linked to Shiga toxin–producing
bacteria. Approximately half of the patients with aHUS have
mutations in genes that regulate complement system: Either
loss-of-function mutations in genes that encode inhibitors of the
alternative pathway of the complement system (e.g., factor H or
I, CFH or CFI, membrane co-factor protein, factor H–related
proteins, C4b-binding protein) or gain-of-function mutations of
genes that encode factor B and C3. Antibodies against CFH
have been observed in 2 to 10% of patients.
Thrombomodulin is a ubiquitous transmembrane endothelial
cell glycoprotein that suppresses clot formation, inhibits fibri-
nolysis, interferes with inflammation, and inactivates some
complement-derived anaphylatoxins.
Delvaeye et al. studied 152 patients who had aHUS and were
recruited from the International Registry of Recurrent and Fa-
milial HUS/Thrombotic Thrombocytopenic Purpura and 380
control subjects. They sequenced the entire coding region of the
thrombomodulin gene (THBD), which lacks introns. Six het-
erozygous mutations of THBD were identified in seven (4.6%)
unrelated patients. Two of them belonged to families with
aHUS. In one of these families, four heterozygous carriers
(including adults) were asymptomatic. As in complement de-
fects, the THBD mutation is not sufficient by itself to cause
HUS. Low serum C3 levels were measured in four patients. The
disease was evident during childhood, from 6 mo to 15 yr of
age. Three of seven patients progressed to ESRD. Four had
recurrent aHUS. One patient developed a first episode of aHUS
after kidney transplantation at 15 yr of age. Further studies will
indicate whether there is a risk for recurrence of aHUS after
kidney transplantation.
In vitro studies on cultured cells showed that thrombomodu-
lin provides protection against complement activation. In ad-
dition, thrombomodulin binds to C3 and CFH and negatively
regulates complement by accelerating CFI-mediated inactiva-
tion of C3b in the presence of co-factors CFH and C4b. Cultured
cells that express THBD variants that are associated with aHUS
had diminished capacity to inactivate C3b and to activate pro-
carboxypeptidase B and thus were less protected from acti-
vated complement. In patients with aHUS, genetic testing
should include several genes that encode proteins that regulate
complement system, including thrombomodulin.
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